142 related articles for article (PubMed ID: 38106221)
1. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips AH; Khoury J; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris RS; Nasr LF; Kriwacki RW; Roberts KG; Konopleva M; Jabbour EJ; Mullighan CG
medRxiv; 2023 Dec; ():. PubMed ID: 38106221
[TBL] [Abstract][Full Text] [Related]
2. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips A; Khoury JD; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris R; Nasr LF; Kriwacki R; Roberts KG; Konopleva MY; Jabbour EJ; Mullighan CG
Blood; 2024 Mar; ():. PubMed ID: 38551807
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
4. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
5. Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Fingrut W; Davis W; McGinnis E; Dallas K; Ramadan K; Merkeley H; Leitch H; Abou Mourad Y; Cassaday RD; Ross C; Léger C
Curr Oncol; 2020 Dec; 28(1):252-259. PubMed ID: 33704192
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aujla A; Aujla R; Liu D
Biomark Res; 2019; 7():9. PubMed ID: 31011424
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
10. Inotuzumab Ozogamicin: First Pediatric Approval.
Dhillon S
Paediatr Drugs; 2024 May; ():. PubMed ID: 38780741
[TBL] [Abstract][Full Text] [Related]
11. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia.
Yilmaz M; Richard S; Jabbour E
Ther Adv Hematol; 2015 Oct; 6(5):253-61. PubMed ID: 26425338
[TBL] [Abstract][Full Text] [Related]
12. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
McDonald GB; Freston JW; Boyer JL; DeLeve LD
Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
[TBL] [Abstract][Full Text] [Related]
13. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
Sartor C; Arpinati M; Chirumbolo G; Dozza L; Cristiano G; Nanni J; Marconi G; Robustelli V; Vigliotta I; Parisi S; Terragna C; Testoni N; Paolini S; Martinelli G; Curti A; Cavo M; Papayannidis C
Hematol Oncol; 2022 Oct; 40(4):734-742. PubMed ID: 35618655
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
Uy N; Nadeau M; Stahl M; Zeidan AM
J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI
Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar T; Szabo A; Wadleigh M; Liedtke M; Arslan S; Siebenaller C; Aldoss I; Schultz E; Hefazi M; Litzow MR; Kuo E; Wang A; Curran E; Shallis RM; Podoltsev N; Balasubramanian S; Yang J; Mattison R; Burkart M; Dinner S; Advani A; Atallah E
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):556-560.e2. PubMed ID: 32291234
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
Paul MR; Wong V; Aristizabal P; Kuo DJ
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
[TBL] [Abstract][Full Text] [Related]
19. Loss of CD22 expression and expansion of a CD22
Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
[TBL] [Abstract][Full Text] [Related]
20. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
